$CTOR

CITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001851484 0001851484 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Citius Oncology (Nasdaq: CTOR) reported commercial progress for LYMPHIR (denileukin diftitox-cxdl). It said new institutional accounts ordering LYMPHIR rose 78% quarter over quarter to 42 institutions, and wholesaler vial orders increased 31% in Q2 2026. Company estimates the initial CTCL market exceeds $400 million.

Citius Oncology (Nasdaq: CTOR) said it is expanding its LYMPHIR launch team, adding 21 field commercial professionals and eight medical science liaisons, with nationwide onboarding expected by August 2026. The buildout was facilitated by May 2026 financing and executed by EVERSANA. The company cites near 100% payer coverage and expects continued order and patient adoption growth in 2H 2026.

Citius Pharmaceuticals (Nasdaq: CTXR) secured $3.8 million in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program. This funding, obtained on February 24, 2026, strengthens the company's financial flexibility. The capital is designated to support the commercial launch of LYMPHIR and advance its late-stage pipeline programs.

Citius Oncology, a subsidiary of Citius Pharmaceuticals, has signed an exclusive distribution agreement with Unipha to make Lymphir (denileukin diftitox-cxdl) available outside the USA. This marks Citius Oncology's third international distribution partnership, expanding global access for their targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). Lymphir is intended for Stage I-III CTCL cases after at least one prior systemic therapy.

Citius Pharmaceuticals ( NASDAQ:CTXR ) , a late-stage biopharmaceutical company focused on developing and commercializing critical care therapies, reported its earnings for the fiscal third quarter of 2025 on August 12, 2025.

Citius Oncology ( NASDAQ:CTOR ) , a biopharmaceutical company focused on cancer treatments, released results for its fiscal third quarter on August 12, 2025. The most pivotal news was an upside surprise on loss per share, reported at ( $0.08 ) GAAP for the quarter, $0.07 better than analyst ...

Shares of Sequans Communications S.A. SQNS rose sharply in today's pre-market trading after the company announced a $384 million strategic investment to launch a bitcoin treasury initiative. Sequans Communications shares jumped 42.2% to $2.72 in the pre-market trading session.

Citius announces a distribution services agreement with Cardinal Health. Cardinal serves as an authorized distributor of record for Citius Oncology, providing specialty pharmaceutical distribution services. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keybanc analyst Ashley Owens downgraded the rating for Deckers Outdoor Corporation DECK from ...